Futura Medical Share Discussion Threads

[thebutler] 25/9/2023 08:16

Plummeting towards the low 40s, exactly like I said it would. Level 2 very weak. If 45p is broken, it looks like a sharp decline to sub 40p.

[petroc] 24/9/2023 10:05

Looks like Glavey is back on the night shift, playing with his crayons.

[glavey] 24/9/2023 04:56

Erexon: 254 out of 335 (76%) reviewers recommend this product

Eroxon: 281 out of 378 (74.34%) reviewers don't recommend this product

[glavey] 24/9/2023 04:50

Not on your head, surely?

[petroc] 23/9/2023 09:56

If the cap fits, looser...

[thebutler] 22/9/2023 10:56

LOL!!! Trialling a placebo against a placebo, that should be fun, especially if the placebo performs better than eroxon. Now that would be hilarious!!!

Update on Amazon: the negative reviews continue to pour in with monthly sales falling to 3k. Also ranks 1,191 in "Health and Personal Care" sales after at one stage being about 300.

The words "slippery" and "slope" spring to mind.

[beanol] 21/9/2023 20:47

I should have qualified by adding "on their own". If you have reviews covering a span of countries then that's a much more statistically valid measurement and less liable to being manipulated.

[broomrigg] 21/9/2023 17:41

MDI sounds like LBO to me.

[glavey] 20/9/2023 11:04

Yes. Gerund form of "loose". As in 'letting go of', 'releasing' etc... As in 'down the loo'.

[onedayrodders] 20/9/2023 10:55

BEANOL ... "The Amazon/Boots reviews valid or not start to become much less relevant given the more international future prospects of the company." ... really, how's that ?

If they are an accurate reflection then the feedback will be the same whether it's Charles, Jurgen, Wang Lee, Claude, Diego, Delroy or Costa placing the order.

The performance of the product is the same in any language.

The stock price will be supported for some time yet with new region launches.

Key figures will be 12 months from now and of importance will be UK sales, to see if still increasing, flat lining or falling.

[petroc] 20/9/2023 10:48

'Loosing' any money?

[glavey] 20/9/2023 10:30

You too Pet? Blue that is... Oh dear.

BTW, I think you meant "un-invested" and not stand a chance of loosing any money.

[mdi] 19/9/2023 07:52

What is the 'performance obligations' which means the Haleon payment is actually a 'contract liability' until its 'key performance obligation, which is expected to be met in 2024'?'upfront milestone payment which is to be recognised as a Contract Liability until satisfaction of the performance obligations. The key performance obligation, which is expected to be met in 2024'

[glavey] 19/9/2023 07:02

"On course for a very blue day"

Feeling blue? Cheer up, things could be worse...

[beanol] 18/9/2023 09:28

I should add that the cash position because of the upfront payment seems decent.

[beanol] 18/9/2023 09:16

Well these results and the planned roll out in the US especially via such a prestigious partner Haleon formerly part of Glaxo plus the other 'super' potential markets such as the Gulf, Nigeria (high cost may impact here) make the company 'real' and give it a clearly viable future. The Amazon/Boots reviews valid or not start to become much less relevant given the more international future prospects of the company. The market trading turnover is still low ?probably a result of high institutional ownership? And lths profit taking perhaps?Still, market reaction disappointing. The answer may be to go for a US listing but that is expensive.

[ajmace] 18/9/2023 08:55

I think it is pretty clear that Eroxon is far more effective than suggested by the reviews on Amazon and Boots.com

[goldie40] 18/9/2023 08:42

proof of the pudding is in the eating got my friend to buy some he is over the moon with it worked very good telling all his friends could not thank me enough

[j777j] 18/9/2023 08:28

Trinity delta has raised price target to 121p

[j777j] 18/9/2023 07:41

Previous forecasts predicted a 5% markets share so this is staggering and bodes very wellEroxon® sales are on track to exceed expectations versus its original first year forecasts, with Eroxon® expected to gain around a 20% share of the clinically proven ED treatment market, with these being largely incremental, demonstrating encouraging signs of consumer acceptance and repeat purchase. Feedback has been positive, with a very low level of complaints received regarding lack of efficacy and side effects, which the Futura Board believes illustrates a high degree of consumer satisfaction